Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid-Reference-Cited by-同舟云学术

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

Published:2015-11-07 Issue:5 Volume:12 Page:517-526
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Bittner Tobias¹,Zetterberg Henrik²³,Teunissen Charlotte E.⁴,Ostlund Richard E.⁵,Militello Michael⁶,Andreasson Ulf²,Hubeek Isabelle⁴,Gibson David⁵,Chu David C.⁶,Eichenlaub Udo¹,Heiss Peter¹,Kobold Uwe¹,Leinenbach Andreas¹,Madin Kairat¹,Manuilova Ekaterina¹,Rabe Christina¹,Blennow Kaj²

Affiliation:

1. Roche Diagnostics GmbH Penzberg Germany

2. Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology The Sahlgrenska Academy at University of Gothenburg Mölndal Sweden

3. UCL Institute of Neurology London UK

4. Clinical Chemistry VU University Medical Center Amsterdam The Netherlands

5. Washington University School of Medicine St. Louis MO USA

6. Covance Central Laboratory Services Indianapolis IN USA

Funder

Roche Diagnostics GmbH

Torsten Söderberg Foundation

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2015.09.009

Reference51 articles.

1. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census

2. WimoA JonssonL GustavssonAAvailable at:http://www.alzheimer‐europe.org/EN/Research/European‐Collaboration‐on‐Dementia/Cost‐of‐dementia/Prognosis‐to‐2030. Accessed October 27 2009.

3. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

4. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

5. Injury markers predict time to dementia in subjects with MCI and amyloid pathology

Cited by 241 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CSF 14–3-3 zeta(ζ) isoform is associated with tau pathology and cognitive decline in Alzheimer's disease;Journal of the Neurological Sciences;2024-02

2. Uptake of 18F-AV45 in the Putamen Provides Additional Insights into Alzheimer’s Disease beyond the Cortex;Biomolecules;2024-01-29

3. Individuals with Alzheimer's disease and low tau burden: Characteristics and implications;Alzheimer's & Dementia;2024-01-19

4. Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status;Journal of Alzheimer's Disease;2024-01-16

5. Vascular risk burden is a key player in the early progression of Alzheimer’s disease;Neurobiology of Aging;2024-01